PH12016501689B1 - Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof - Google Patents

Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Info

Publication number
PH12016501689B1
PH12016501689B1 PH12016501689A PH12016501689A PH12016501689B1 PH 12016501689 B1 PH12016501689 B1 PH 12016501689B1 PH 12016501689 A PH12016501689 A PH 12016501689A PH 12016501689 A PH12016501689 A PH 12016501689A PH 12016501689 B1 PH12016501689 B1 PH 12016501689B1
Authority
PH
Philippines
Prior art keywords
tatk
compositions
formulations
cdkl5 fusion
fusion proteins
Prior art date
Application number
PH12016501689A
Other languages
English (en)
Other versions
PH12016501689A1 (en
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of PH12016501689B1 publication Critical patent/PH12016501689B1/en
Publication of PH12016501689A1 publication Critical patent/PH12016501689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
PH12016501689A 2014-02-28 2016-08-25 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof PH12016501689A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (2)

Publication Number Publication Date
PH12016501689B1 true PH12016501689B1 (en) 2016-10-03
PH12016501689A1 PH12016501689A1 (en) 2016-10-03

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501689A PH12016501689A1 (en) 2014-02-28 2016-08-25 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA202190727A3 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3608334T3 (enExample)
PT (2) PT3608334T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2018005617A2 (en) * 2016-06-28 2018-01-04 Alma Mater Studiorum - Universitá Di Bologna TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
TW201927825A (zh) * 2017-11-30 2019-07-16 美商阿米庫斯醫療股份有限公司 Cdkl5 表現變體和cdkl5 融合蛋白
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
AU2021392642A1 (en) 2020-12-01 2023-06-22 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815582A1 (en) * 2010-10-25 2012-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Treatment of mecp2-associated disorders
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Also Published As

Publication number Publication date
EP3608334B1 (en) 2021-05-19
AU2015221860B2 (en) 2019-09-12
EP3110837A2 (en) 2017-01-04
AU2015221860A1 (en) 2016-09-08
CR20160392A (es) 2017-06-12
NI201600127A (es) 2017-03-13
DOP2016000220A (es) 2016-12-15
ES2745335T3 (es) 2020-02-28
EP3608334A1 (en) 2020-02-12
SMT202100478T1 (it) 2021-09-14
BR112016019868B1 (pt) 2023-11-28
US10584318B2 (en) 2020-03-10
SV2016005264A (es) 2017-02-15
SG11201606863YA (en) 2016-09-29
HUE045393T2 (hu) 2019-12-30
US10907138B2 (en) 2021-02-02
PH12016501689A1 (en) 2016-10-03
KR102307276B1 (ko) 2021-09-30
HUE055282T2 (hu) 2021-11-29
DK3608334T3 (da) 2021-08-23
US9944910B2 (en) 2018-04-17
WO2015128746A2 (en) 2015-09-03
PT3608334T (pt) 2021-08-25
RS62244B1 (sr) 2021-09-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20150247134A1 (en) 2015-09-03
AU2019219743A1 (en) 2019-09-19
NZ723371A (en) 2023-11-24
ES2885245T3 (es) 2021-12-13
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
US20200199549A1 (en) 2020-06-25
CA2940401C (en) 2022-11-29
MX2016011167A (es) 2017-04-06
IL275435A (en) 2020-08-31
PE20161406A1 (es) 2017-01-14
BR112016019868A2 (pt) 2017-10-17
KR20170002372A (ko) 2017-01-06
ZA201606655B (en) 2020-05-27
CL2016002142A1 (es) 2017-09-08
MX2020001223A (es) 2022-05-31
MX392778B (es) 2025-03-24
CY1124727T1 (el) 2022-07-22
JP2020062022A (ja) 2020-04-23
EA201691691A1 (ru) 2017-05-31
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
CA2940401A1 (en) 2015-09-03
US20180327725A1 (en) 2018-11-15
PL3110837T3 (pl) 2020-04-30
JP6896050B2 (ja) 2021-06-30
AU2019219743B2 (en) 2020-10-29
JP6629747B2 (ja) 2020-01-15
WO2015128746A3 (en) 2015-11-26
US9290746B2 (en) 2016-03-22
IL247481B (en) 2020-07-30
HRP20191511T1 (hr) 2019-11-29
US20160194617A1 (en) 2016-07-07
LT3110837T (lt) 2019-10-10
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
PT3110837T (pt) 2019-09-12
SI3110837T1 (sl) 2019-12-31
RS59344B1 (sr) 2019-10-31
PL3608334T3 (pl) 2021-11-22
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
JP2017507655A (ja) 2017-03-23
EA038000B1 (ru) 2021-06-22
SI3608334T1 (sl) 2021-11-30
EA202190727A2 (ru) 2021-07-30
SMT201900504T1 (it) 2019-11-13
EP3110837B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2019007020A (es) Anticuerpos il-11.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
MX2019007021A (es) Anticuerpos il-11ra.
IL312989A (en) Il15/il15rα heterodimeric fc-fusion proteins
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MY191581A (en) Anti-pd-1 antibodies
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
CA3287905A1 (en) Compositions, cell constructs, and methods of making and using the same
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2020012893A (es) Formulaciones de proteinas.
MY193650A (en) Extracellular matrix compositions
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
EP3503911A4 (en) COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME
HK40010491A (en) Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
WO2015184326A8 (en) Conjugates, particles, compositions, and related methods